Filters
Treatment with the oral interleukin-1β blocker diacerein appears minimally beneficial for reducing pain in patients with knee osteoarthritis (OA), as shown in a study.
Frailty appears predictive of an increased risk of osteoarthritis (OA) incidence and falls, as well as disease progression, in older adults, a study has shown. However, no association exists between frailty and joint replacement surgery-free time.
Rheumatoid arthritis (RA) appears to contribute to the development of interstitial lung disease (ILD), as shown by genetic evidence from a Mendelian randomization (MR) study.
The use of Renal Activity Index for Lupus (RAIL) score helps to detect active lupus nephritis (LN) and to calculate the course of adult LN, suggests a recent study.
Systemic sclerosis (SSc) patients using hydroxychloroquine have reduced mortality, although they appear to have a higher prevalence of pulmonary hypertension compared with their peers who do not use the drug, according to a retrospective study.
The presence of certain autoantibodies in patients with systemic sclerosis (SSc) is predictive of interstitial lung disease (ILD) progression, suggests a Singapore study.
Three months of romosozumab followed by 9 months of denosumab works just as well as 12 months of romosozumab for increasing bone mass in postmenopausal women at high risk of fracture, as shown in an open-label, noninferiority trial.
A novel ultrasonographic scoring model integrating precise definitions for each stage of salivary gland (SG) hypofunction addresses the clinical heterogeneity seen in patients with Sjögren disease (SjD) and demonstrates accuracy in reflecting three distinct stages of SG secretion function, reveals a study.
Quality of life (QOL) among patients with systemic lupus erythematosus (SLE) improves following CD19 chimeric antigen receptor (CAR) T cell therapy, with also helps lessen the socioeconomic burden associated with active disease, a study has shown.
Treating gout patients with urate-lowering therapy (ULT) to meet a serum urate level below 6 mg/dL within 12 months results in a reduced risk of major adverse cardiovascular events, as shown in a new user cohort study.
